Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System.
Yang BaiBin WuLiangwen GouZhenwei FangTing XuTiejun ZhangYuwen LiPublished in: Journal of clinical medicine (2023)
Compared with allopurinol, febuxostat may increase cardiovascular toxicity in patients with gout.